Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

145.85 +0.58 (+0.40%)
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
Johnson & Johnson is negotiating with plaintiffs' lawyers opposing its $6.48 billion talc settlement, 
Via Benzinga
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
From Johnson & Johnson
Via Business Wire
2 Unstoppable Stocks That Are Screaming Buys in August
These stocks have quality businesses behind them. 
Via The Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
Some of Trump's Dividend Kings deserve a crown more than others. 
Via The Motley Fool
Topics Government
Exposures Political
Is Johnson & Johnson Stock a Buy?
The company hasn't performed well in recent years, 
Via The Motley Fool
Johnson & Johnson Unusual Options Activity
Via Benzinga
Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
A Big CEO Move, Big Buffett Buys, and More
Motley Fool analysts talk over market news including earnings updates from Home Depot, Walmart, and Brinker. 
Via The Motley Fool
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
This leading pharmaceutical stock is flying under the radar right now. 
Via The Motley Fool
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
Johnson & Johnson to acquire V-Wave for $600 million with potential $1.1 billion in milestone payments. Deal boosts JNJ MedTech's cardiovascular portfolio. Also, FDA approves Rybrevant-Lazcluze combo... 
Via Benzinga
Exposures Product Safety
4 Defensive Stocks to Combat Market Fear, Uncertainty, and Doubt
Shield your investments from market volatility with these four resilient defensive stocks, offering stability and potential growth despite uncertainty. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Exploring NYSE:JNJ's dividend characteristics.
Why the dividend investor may take a look at JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
Johnson & Johnson to Acquire V-Wave
From Johnson & Johnson
Via Business Wire
5 Dividend Growth Stocks to Buy and Hold Forever
Dividend growth stocks offer investors a powerful combination of income and capital appreciation potential, making them attractive for long-term portfolios. 
Via The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
ETFs offer a good way to own a diversified portfolio of income-producing equities. 
Via The Motley Fool
Topics ETFs
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
Investors seeking reliable dividend growth want to start with these two members of the Dow Jones Industrial Average. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Top Dividend ETFs That Investors can Buy and Hold for Decades
You won't have to worry about tracking individual dividend stocks anymore with these funds. 
Via The Motley Fool
Topics ETFs
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
Johnson & Johnson Nears Approval for $6.5B Long Standing Talc Settlement
Johnson & Johnson seeks to resolve thousands of lawsuits through bankruptcy proceedings, facing both legal challenges and critical milestones. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Exposures Interest Rates
CrowdStrike: What's Ahead For Cybersecurity Player In The Wake Of Its Corporate Crisis
After it botched a cybersecurity software update, CrowdStrike stock is paying the price. A crisis management challenge lies ahead. 
Via Investor's Business Daily
Nvidia Looks To Disrupt The Health Care Industry With AI
Nvidia is a dominant force in the artificial intelligence revolution. Now its computing platforms are disrupting the health care industry. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions. 
Via InvestorPlace
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets. 
Via InvestorPlace
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
Exposures COVID-19
J&J Moves Closer to Resolving Baby Powder Lawsuits, 75% of Plaintiffs Support $6.5B Settlement
Johnson & Johnson secures over 75% support for a $6.5 billion settlement plan to resolve thousands of lawsuits over claims that its talc-based baby powder caused cancer. The company faces ongoing legal... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Blue-Chip Stocks to Buy on the Dip: August 2024
These blue-chip stocks are well-positioned to provide positive returns to investors due to their high growth potential. 
Via InvestorPlace
Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies
Medicare beneficiaries face higher costs for Johnson & Johnson's Stelara due to a shift in coverage from Part B to Part D. The OIG report shows a nearly tenfold increase in Medicare spending on... 
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in August
These longtime winners still have a lot to offer. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.